It is currently unknown whether HIF2α inhibitors (e.g. belzutifan) are effective for SDHB-mutant PCPG, but it is plausible that co-operative EPAS1 mutations could make these tumours more sensitive65. The gene discussed is EPAS1; the disease is neoplasm.